Advertisement
Advertisement
U.S. markets open in 8 hours 30 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Silence Therapeutics plc (SLN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
23.00+1.00 (+4.55%)
At close: 03:58PM EST
23.00 0.00 (0.00%)
After hours: 04:04PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close22.00
Open22.00
Bid22.07 x 900
Ask0.00 x 1400
Day's Range21.00 - 23.05
52 Week Range17.25 - 35.00
Volume24,797
Avg. Volume4,527
Market Cap688.349M
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-1.95
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2,373.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SLN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Silence Therapeutics Plc - Amer
    Daily – Vickers Top Buyers & Sellers for 02/02/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • GlobeNewswire

    Silence Therapeutics to Present at Jefferies London Healthcare Conference

    Silence Therapeutics to Present at Jefferies London Healthcare Conference 11 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies London Healthcare Conference being held November 16-18, 2021. The on-dema

  • GlobeNewswire

    Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder

    Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder 5 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that a leading healthcare focused investment firm, Frazier Life Sciences Public Fund, purchased approximately $20 millio

  • GlobeNewswire

    Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

    Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication being assessed using endogenous hepcidin modulation SLN360 single-ascending dose study on-track for topline data in Q1’22 – independent review committee recommends extending follow-up period to assess potential longer duration of actionAdvancing mRNAi GOLD™ platform programs – poised to deliver 2-3 INDs pe

Advertisement
Advertisement